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INTRODUCTION
Craniopharyngioma (CP) is the commonest suprasellar brain
tumor and it constitutes 6–10% of pediatric brain tumors [1].
Although the tumor is slow growing and benign, managing
long-term co-morbidities following surgery is challenging [2]. A
common complication is the development of varying degrees of
hypopituitarism (HP) which warrants long-term replacement of
various hormones including estrogen and progesterone in girls at
the onset of adolescence [3]. Deep venous thrombosis (DVT) has
been occasionally reported in patients with CP [4–6]. In the
immediate post-operative period multiple risk factors contribute
to the development of DVT. Another potentially high risk period
for DVT is during the initiation of estrogen and progesterone
replacement therapy (HRT) in females with HP. Although the risk
of DVT in association with HRT for post-menopausal women has
been investigated, the risk for development of DVT in adolescent
girls requiring HRT for HP has not been well studied. We report
three female patients, who developed DVT after CP surgery, and
highlight their unique risk factors for thrombosis, their management
and discuss the need for an individualized approach to treatment.
METHODS
Our center has followed 34 patients with CP over the last 14
years, of which 3 patients developed DVT. All patients were
investigated for thrombophilia (Table I) as per the recommen-
dations of Perinatal and Pediatric Haemostasis Subcommittee of
the Scientific and Standardization Committee of the International
Society on Thrombosis and Haemostasis (ISTH) [7].
RESULTS
Case 1
A 16-year-old Caucasian female presented with left leg swel-
ling after traveling for 6 hr. Ultrasound (US) showed non-visual-
ization of the deep venous structures and venography confirmed
extensive ileofemoral DVT. Her past medical history was signifi-
cant for partial HP after resection of CP at 3 years of age. She was
on thyroid replacement and 2 months prior to this event she was
started on HRT with oral contraceptive pills (OCP) containing
drospirenone (3.0 mg) and ethinyl estradiol (0.030 mg). Family
history was significant for DVT in paternal aunt and cousin, both
related to OCP use. Her OCP was stopped, and she was treated
initially with therapeutic unfractionated heparin and later transi-
tioned to enoxaparin for 6 months. Repeat imaging at the end of
therapy showed complete resolution of thrombosis. Her thrombo-
philia work up showed that she was heterozygous for Factor V
Leiden (FVL) and plasminogen activator inhibitor-1 (PAI-1)
mutation (4G/5G). After discussing the risk for recurrent throm-
bosis and the option of giving prophylactic anticoagulation
therapy with HRT, the family elected to stop all HRT. Two years
after stopping enoxaparin she has had no recurrence of DVT.
Case 2
A 13-year-old Caucasian female diagnosed with CP underwent
total surgical resection. Following surgery, she developed panhy-
popituitarism and diabetes insipidus (DI) for which she was
started on replacement therapy with hydrocortisone, synthroid,
and intranasal desmopressin. Her immediate post-operative period
was complicated by left sided hemiparesis due to right middle
cerebral artery territory infarction. Two weeks later she developed
extensive bilateral lower extremity DVT with extension into the
inferior vena cava. A Gunther-Tulip inferior vena cava (IVC) filter
was placed and she was subsequently treated with unfractionated
heparin. She had strong family history of DVT in maternal grand-
mother, maternal great-grandmother, and maternal aunt; all of
them were on coumadin. Thrombophilia work up revealed that
she had elevated Von Willebrand factor Antigen (vWFAg) level of
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403% (range 49–156%), factor VIII (FVIII) activity of 418%
(range 63–150%) and PAI levels of >100 IU/ml (range 0–
14 IU/ml) and further genetic studies showed she was homozy-
gous for PAI-1(4G/4G) polymorphism. She was transitioned to
therapeutic enoxaparin for six months. During follow up she
developed hypothalamaic hyperphagia leading to morbid obesity,
type 2 diabetes mellitus, severe osteoporosis, narcolepsy, and
seizures. Two years following the initial presentation, HRT was
initiated. Since she had multiple risk factors for recurrence of
DVT (Table II), prior to initiation of HRT she was started on
prophylactic enoxaparin 80 mg daily. Three years after the
initiation of enoxaparin she continues to be on HRT without
recurrence of DVT.
Case 3
A 5-year-old Caucasian female underwent surgical resection
after diagnosis of CP. Following surgery, she developed
panhypopituitarism and DI for which she was started on replace-
ment therapy with hydrocortisone, synthroid, and intranasal
desmopressin. Two months following surgery she was admitted
with right leg swelling and altered sensorium. She was noted to
have severe hypernatremic dehydration with serum sodium of
175 meq/L. Doppler US of right leg showed extensive ileofemoral
DVT. She was started on unfractionated heparin and later changed
to therapeutic enoxaparin for a total duration of 3 months. Repeat
imaging at 3 months showed resolution of DVT. She had a strong
family history of thrombosis, paternal grandfather died of
myocardial infarction at the age of 40 years and maternal uncle
had DVT when he was 30 years of age. Thrombophilia screening
revealed elevated vWFAg of 258% (range 49–156%), FVIII of
204% (range 63–150%), and the presence of homozygous 5,10-
methylenetetrahydrofolate reductase (MTHFR) 677C>T variant
with a normal serum homocysteine level. On follow-up, her DI is
stable on desmopressin replacement. Due to her age, she has not
required HRT currently. However, as thrombophilia screening has
not revealed any known thrombosis predisposing mutations, our
recommendation is to start low dose HRT without prophylactic
anticoagulation with ongoing clinical monitoring for thrombosis.
DISCUSSION
Multiple co-morbidities following craniopharyingioma surgery
predispose patients to the development of DVT. In the immediate
post-operative period, prolonged immobilization with the release
of procoagulant substance and the presence of central venous
catheters are some of the known risk factors. Additionally,
acquired risk factors that develop as a consequence of surgery
predispose them to DVT. These include obesity and metabolic
syndrome secondary to hypothalamic hyperphagia [8], desmo-
pressin replacement therapy [4], and estrogen replacement
therapy [9].
Both inadequate desmopressin replacement and desmopressin
therapy has been reported to be associated with thrombosis [4,10–
12]. Furtado et al. [4] reported two cases of IVC thrombosis
following CP surgery. The thrombosis was attributed to severe
dehydration leading to hemoconcentration due to inadequate
replacement of desmopressin [4]. In patients on desmopressin
therapy, it has been reported to release vWF multimers and
TABLE I. Thrombophilia Testing for Patients With Deep Venous
Thrombosis
Thrombophilic trait Method for testing
Level I Factor V Leiden PCR-RFLP











Factor VIII One stage clotting assay
vWF Immunoassay
Level IIa PAI-1 PCR-RFLP
MTHFR PCR-RFLP
PCR-RFLP, polymerase chain reaction-restriction fragment length
polymorphism; FPIA, fluorescence polarization immunoassay;
NIPIA, near-infrared particle immunoassay; PAI-1, plasminogen
activator inhibitor-1(4G/4G) polymorphism; MTHFR, methylenete-
trahydrofolate reductase 677C>T variant. aTests based on clinical
history and Level I results.
TABLE II. Risk Factors and Management of DVT in Children With Craniopharyngioma
Patient 1 Patient 2 Patient 3
DVT Yes Yes Yes
Trigger OCP Multiple Hypernatremic dehydration
Prolonged travel
Family history of DVT Yes Yes Yes
Ongoing risk Heterozygous-FVL High PAI-1 levels Homozygous-MTHFR
Heterozygous-PAI-1 Homozygous-PAI-1
Obese High vWFAg and factor VIII High vWFAg and factor VIII
Non-ambulatory
Metabolic syndrome
Anticoagulation (enoxaprin) Stopped Continueda Stopped
HRT No Yes Yes
Needs prophylactic anticoagulation




as risk factors resolved
OCP, oral contraceptive pills; FVL, Factor V Leiden; PAI-1, plasminogen activator inhibitor-1(4G/4G) polymorphism; MTHFR, methylenete-
trahydrofolate reductase 677C>T variant. aContinued in prophylactic dose.
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transiently increase vWF level leading to increased risk of thrombosis
[4,10–12]. High levels of vWF were seen in cases 2 and 3; case 3 also
had associated severe dehydration. However, a large meta-analysis
failed to show a statistically significant increase of thrombosis in
patients who received desmopressin after surgery [13].
In adolescent females with HP HRT is recommended because
estrogen and progesterone are required for initiation of puberty,
fusion of epiphyses, breast development, menstruation, achieve-
ment of peak bone mass, and maintenance of normal adult female
body composition [14]. One of the common means of estrogen-
progesterone hormone replacement (HRT) is by OCP. However,
its use is known to be associated with two- to sixfold increased
risk of DVT [15]. Nevertheless, OCP containing low dose ethinyl
estradiol (0.020 mg) are associated with much lower risk [9].
Also, OCP that contain desogestrel or gestodene (third generation
progesterone) seem to be associated with greater risk than those
that contain levonorgestrel (second generation progesterone) [9].
These factors should be taken into consideration before initiation
of HRT in these patients. Of increasing interest is the use of the
more physiological transdermal estrogen patch for HRT. Although
the risk of developing DVT is similar to standard dose estrogen
containing OCP [16] but when compared to OCP it has the added
advantage of decreased requirement of growth hormone replace-
ment for HP [14].
The risk of DVT increases with the concomitant presence of
associated thrombophilia. All of our three patients had a family
history of thrombosis. Thrombophilic states were identified in
two of our patients, which include; heterozygous FVL and elev-
ated PAI activity with PAI-1 4G/5G polymorphism in case 1,
markedly increased PAI activity with 4G/4G homozygous poly-
morphism in case 2. In case 3, the thermolabile MTHFR mutation
was identified but the homocysteine level was normal. Of all the
potential procoagulant states identified, the risk of DVT with FVL
mutation in patients on HRT has been well studied. Patients with
heterozygous FVL have a five- to tenfold increased risk of DVT
when initiated on OCP [17]. It is controversial whether the PAI
4G/4G polymorphism is a true thrombophilic mutation. Some
reports have shown such an association while others have refuted
this [18,19]. The MTHFR C677T mutation with hyperhomocys-
teinemia is associated with increased risk of thrombosis, but its
significance in the absence of elevated homocysteine is not well
established [20].
In conclusion, children with CP develop multiple co-morbid-
ities that increase the risk for DVT. A detailed family history and
individualized screening for thrombophilia may be beneficial in
prevention and management of DVT and HRT.
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